Shop by goal
Popular compounds
Research resources
Recently viewed
Bryan Johnson's CJC-1295 Experiment: What His 2026 Results Showed
Short answer: In a widely shared 2026 write-up, longevity self-experimenter Bryan Johnson argued that “peptides are not only good” - describing a measured trial of CJC-1295 , a growth-hormone-releasing-hormone (GHRH) analog, that he says produced unwanted markers rather than clean benefits. It is one of the most useful celebrity data points precisely because it is skeptical : a quantified n-of-1 that pushes against the “peptides fix everything” narrative. Editorial note: New-U reports independent press coverage here; Bryan Johnson is not affiliated with or endorsing New-U, and nothing here is medical advice.
Most celebrity peptide coverage is enthusiastic. Bryan Johnson’s is not - and that is what makes it worth reading carefully. Known for the extreme self-measurement of his longevity project, Johnson published a 2026 account (widely circulated via his Substack) titled around the idea that people mistakenly believe peptides are only good . He described running CJC-1295 and reported that his own biomarker tracking turned up adverse signals. This page summarises that public account and pairs it with what the CJC-1295 research literature actually describes - it is not medical advice, and Johnson is not affiliated with New-U.
What did Bryan Johnson say about CJC-1295?
Per his own 2026 write-up, Johnson approached CJC-1295 the way he approaches everything: as a measured experiment with before-and-after data rather than a vibe. His public framing was that the compound did not deliver the clean upside he had hoped for, and that some of the markers he tracks moved in the wrong direction - the basis for his broader argument that peptides carry real trade-offs and are “not only good.” We are reporting the existence and thrust of that account; readers should consult his primary post for the exact metrics he cites, and remember an n-of-1 is a data point, not a trial.
What is CJC-1295?
CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH). In the research literature it is studied for its ability to stimulate the body’s own pulsatile release of growth hormone, and it is frequently paired with a growth-hormone secretagogue such as ipamorelin. It comes in two forms - with and without DAC (drug affinity complex), which changes the half-life. Our CJC-1295 + ipamorelin research guide covers the mechanism, and hexarelin vs CJC-1295 compares it with a different secretagogue class.
Why a skeptical data point matters
The value of Johnson’s account is not that it “proves” CJC-1295 is harmful - one person’s biomarkers cannot do that. Its value is that it models the right posture: measure, don’t assume. Growth-hormone-axis compounds can shift IGF-1, glucose handling and other markers, which is exactly why they belong in a monitored research context rather than a casual one. When a high-profile figure whose entire brand is optimisation reports a compound didn’t optimise him, that is a healthy counterweight to the influencer enthusiasm that dominates the rest of this beat.
The honest caveat. Johnson’s report is a single, self-documented experiment - it is neither a clinical trial nor evidence that the compound is safe or unsafe for anyone else. A public figure naming a compound is a cultural signal, not clinical proof. For the framework we use to separate a public statement from an approved medicine from a preliminary research compound, see celebrity peptide claims vs scientific research.
Frequently Asked Questions
What peptide did Bryan Johnson experiment with? In a 2026 public write-up he described a measured self-experiment with CJC-1295 (a GHRH analog) and reported adverse markers - arguing peptides are “not only good.” Reported as his public account, not medical advice.
What is CJC-1295? A synthetic GHRH analog studied for stimulating the body’s own growth-hormone release, often paired with ipamorelin; sold in DAC and no-DAC forms. Supplied for laboratory research use only.
Does his result mean CJC-1295 is dangerous? No - an n-of-1 is a data point, not a trial, and cannot establish safety or harm for others. Its value is the “measure, don’t assume” posture. Nothing here is medical advice.
Is Bryan Johnson endorsing New-U? No. This reports his independent public write-up. He is not affiliated with or endorsing New-U; nothing here is medical advice. Materials are research use only.
Related Reading
From the Lab - Peptides on LinkedIn & Facebook
Lab-Verified Research Peptides
New-U Research Compounds stocks CJC-1295 (no DAC) and every compound named above in sealed 10-vial packs, independently verified by Janoshik and Freedom Diagnostics for >99% purity. Research use only - not for human consumption.
Research-grade · >99% HPLC purity · COA per lot
Buy research peptides from New-U Research Compounds
Lab-verified by Janoshik Analytical (RP-HPLC + ESI-MS), sealed vials, discreet tracked worldwide shipping. For laboratory research use only — not for human consumption.
Premium research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical with a Certificate of Analysis on every lot. Shipped lab-direct, discreet and cold-chain, worldwide. For laboratory research use only.
Shop
Learn
Company
Support
Ways to Pay
Shop by Compound
Shop by Goal
Ships worldwide
Research use only (RUO). All products are sold strictly for laboratory and research purposes — not for human or veterinary consumption. Purchasers must be 21 or older.
All rights reserved. Copyright of New-U held with Hilxera Distribution Services LLC 2026.
Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.
© 2026 New-U Research Compounds · new-u.io · @new.u.io